Trial Profile
Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 Nov 2016 Status changed from recruiting to completed.
- 19 Dec 2013 New trial record